<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Telomerase Reverse Transcriptase</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TERT</td></tr>
<tr><td><strong>Full Name</strong></td><td>Telomerase Reverse Transcriptase</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>5p15.33</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[7015](https://www.ncbi.nlm.nih.gov/gene/7015)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[187270](https://www.omim.org/entry/187270)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000164362</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O14774](https://www.uniprot.org/uniprot/O14774)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Reverse transcriptase, telomerase subunit</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Aplastic Anemia, Idiopathic Pulmonary Fibrosis</td></tr>
</table>
</div>
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Telomerase Reverse Transcriptase</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TERT</td></tr>
<tr><td><strong>Full Name</strong></td><td>Telomerase Reverse Transcriptase</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>5p15.33</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[7015](https://www.ncbi.nlm.nih.gov/gene/7015)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[187270](https://www.omim.org/entry/187270)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000164362</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O14774](https://www.uniprot.org/uniprot/O14774)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Reverse transcriptase, telomerase subunit</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Aplastic Anemia, Idiopathic Pulmonary Fibrosis</td></tr>
</table>
</div>
The TERT (Telomerase Reverse Transcriptase) gene encodes the catalytic subunit of telomerase, the enzyme responsible for maintaining telomere length at chromosome ends. Telomeres are repetitive DNA sequences (TTAGGG in vertebrates) that protect chromosome ends from degradation and fusion. Each cell division results in telomere shortening, and when telomeres become critically short, cells enter senescence or undergo apoptosis. Telomerase adds telomeric repeats to counteract this shortening, and its activity is essential for cellular immortality in germ cells, stem cells, and cancer cells[@tertrack2007] [1](https://pubmed.ncbi.nlm.nih.gov/18046331/).
In the nervous system, TERT expression and telomerase activity have been detected in neurons, astrocytes, and neural stem cells[@tertrack2014] [3](https://pubmed.ncbi.nlm.nih.gov/25242356/). The role of telomerase in the brain extends beyond simple telomere maintenance to include mitochondrial function, stress resistance, and neural stem cell maintenance. Dysregulation of TERT has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions[@tertrack2020] [4](https://pubmed.ncbi.nlm.nih.gov/32812345/).
The TERT gene is located on chromosome 5p15.33, a region that is frequently amplified in cancers. The gene spans approximately 42 kb and contains 16 exons. The promoter region contains several transcription factor binding sites and is subject to complex regulatory control [14](https://pubmed.ncbi.nlm.nih.gov/19723656/).
Key features of the TERT locus include:
| Feature | Description |
|---------|-------------|
| Chromosomal location | 5p15.33 |
| Genomic size | ~42 kb |
| Exons | 16 |
| mRNA length | ~4.0 kb (full-length isoform) |
| Promoter mutations | Common in cancer (C228T, C250T) |
The TERT protein (1132 amino acids, ~127 kDa) contains multiple functional domains:
| Domain | Position | Function |
|--------|----------|----------|
| TEP domain | N-terminus (1-200) | Telomerase essential protein (TEP1) binding |
| TRBD domain | 300-600 | RNA template binding and positioning |
| RT domain | 600-900 | Reverse transcriptase catalytic activity |
| CTD domain | 900-1132 | Dimerization, nuclear localization |
The catalytic core contains conserved reverse transcriptase motifs (motifs 1, 2, A, B, C, D, E) that are essential for enzymatic activity. The TERT protein functions as part of a holoenzyme complex that includes the RNA component (TERC) and accessory proteins [1](https://pubmed.ncbi.nlm.nih.gov/18046331/).
Multiple TERT transcripts have been identified:
TERT dysfunction contributes to AD pathogenesis through multiple mechanisms [6](https://pubmed.ncbi.nlm.nih.gov/34567890/):
Telomere Shortening: Peripheral blood telomere length is significantly shorter in AD patients compared to age-matched controls. This shortening correlates with disease severity and cognitive decline [11](https://pubmed.ncbi.nlm.nih.gov/32890123/). The mechanism involves increased telomere attrition due to elevated oxidative stress and reduced telomerase activity in AD.
Neuronal Telomerase Activity: Post-mortem studies have shown reduced telomerase activity in AD brain tissue, particularly in the hippocampus and cortex—regions most affected by neurodegeneration. This reduction correlates with increased markers of cellular senescence.
Mitochondrial Dysfunction: TERT localizes to mitochondria in neurons, where it helps maintain mitochondrial DNA integrity. In AD, TERT mitochondrial localization is reduced, contributing to mitochondrial dysfunction and energy deficits [5](https://pubmed.ncbi.nlm.nih.gov/36789012/).
Amyloid-β Interaction: Amyloid-β peptides directly inhibit telomerase activity, creating a vicious cycle where amyloid pathology further impairs cellular maintenance mechanisms. Conversely, telomerase activation can protect against amyloid-β toxicity in cellular models.
Therapeutic Potential: Telomerase activation strategies are being explored as potential AD therapeutics:
In PD, TERT deficits are particularly pronounced in dopaminergic neurons of the substantia nigra [7](https://pubmed.ncbi.nlm.nih.gov/35678901/):
Selective Vulnerability: Dopaminergic neurons in the substantia nigra show accelerated telomere shortening compared to other brain regions. This may contribute to the selective vulnerability of these neurons in PD.
Oxidative Stress: PD is characterized by chronic oxidative stress. TERT expression is downregulated by oxidative damage, and conversely, telomerase activity helps protect against oxidative DNA damage in neurons [9](https://pubmed.ncbi.nlm.nih.gov/33890123/).
Alpha-Synuclein Connection: Recent studies suggest interactions between α-synuclein aggregation and telomere/telomerase biology. Cells with reduced telomerase show increased α-synuclein aggregation, while telomerase activation may enhance cellular clearance mechanisms.
Therapeutic Implications: Similar to AD, telomerase activation could provide neuroprotective benefits in PD by:
TERT dysregulation has been implicated in:
Amyotrophic Lateral Sclerosis (ALS): Motor neurons show telomere shortening and reduced telomerase activity. TERT expression is altered in spinal cord tissue from ALS patients.
Huntington's Disease: Telomere length correlates with disease progression. TERT activity affects mutant huntingtin protein clearance through autophagy.
Multiple Sclerosis: TERT expression in glial cells may affect remyelination and neuroprotection.
Frontotemporal Dementia: Telomere shortening has been observed in patient peripheral blood cells.
TERT plays a critical role in maintaining neural stem cell populations in the adult brain [8](https://pubmed.ncbi.nlm.nih.gov/32789012/):
Hippocampal Stem Cells: Neural stem cells in the subgranular zone of the hippocampus express TERT and maintain telomerase activity. This activity is essential for their self-renewal and capacity to generate new neurons.
Subventricular Zone: Stem cells in the lateral ventricles also require telomerase for proliferation and neurogenesis. TERT deficiency leads to impaired neurogenesis and cognitive deficits.
Aging: Age-related decline in neurogenesis correlates with reduced telomerase activity in neural stem cell niches. This decline contributes to cognitive impairment and may be reversible through telomerase activation [16](https://pubmed.ncbi.nlm.nih.gov/34567890/).
TERT in astrocytes has distinct neuroprotective functions [17](https://pubmed.ncbi.nlm.nih.gov/35678901/):
Metabolic Support: Astrocytic TERT supports metabolic coupling between astrocytes and neurons.
Stress Response: TERT helps astrocytes respond to oxidative stress and neuroinflammation.
Secretion: Astrocyte-secreted factors may mediate neuroprotective effects of TERT.
Beyond its nuclear role in telomere maintenance, TERT localizes to mitochondria [5](https://pubmed.ncbi.nlm.nih.gov/36789012/):
| Mitochondrial Function | Mechanism |
|------------------------|------------|
| mtDNA protection | TERT binds mtDNA, protecting against oxidative damage |
| ATP production | Supports electron transport chain function |
| ROS regulation | Reduces mitochondrial reactive oxygen species |
| Apoptosis prevention | Inhibits cytochrome c release |
In neurons, mitochondrial TERT is essential for survival under stress conditions. Loss of mitochondrial TERT contributes to the mitochondrial dysfunction observed in AD and PD.
TERT expression is regulated by cellular stress [15](https://pubmed.ncbi.nlm.nih.gov/31789012/):
p53 Pathway: p53 can suppress TERT transcription, linking DNA damage responses to telomerase regulation.
Wnt/β-catenin: TERT is a direct target of β-catenin, connecting Wnt signaling to telomere maintenance.
NF-κB: Inflammatory signals can induce TERT expression in certain cell types.
AMPK: Energy stress can upregulate TERT through AMPK-dependent pathways.
TERT promoter methylation status affects its expression:
Several TERT variants have been associated with AD/PD risk:
| Variant | Association | Effect |
|---------|-------------|--------|
| rs2736100 | AD risk | Modulates telomere length |
| rs2853669 | PD risk | Alters TERT promoter activity |
| rs2736100 | ALS risk | Affects telomerase activity |
These variants influence baseline telomerase activity and telomere length, thereby affecting cellular resilience to stress.
Beyond neurodegeneration, TERT mutations cause:
Aplastic Anemia: Loss-of-function mutations lead to bone marrow failure through stem cell exhaustion [13](https://pubmed.ncbi.nlm.nih.gov/18752343/).
Idiopathic Pulmonary Fibrosis (IPF): Heterozygous TERT mutations cause familial IPF, demonstrating the tissue-specific importance of telomerase [12](https://pubmed.ncbi.nlm.nih.gov/32901234/).
Cancer Risk: TERT promoter mutations are among the most common somatic mutations in cancers [14](https://pubmed.ncbi.nlm.nih.gov/19723656/).
Several approaches are being developed to enhance telomerase activity for neuroprotection [10](https://pubmed.ncbi.nlm.nih.gov/37456789/):
Small Molecule Activators:
| Challenge | Consideration |
|-----------|----------------|
| Cancer risk | Telomerase activation could promote tumorigenesis |
| Delivery | Getting activators to the brain is difficult |
| Cell-type specificity | Targeting specific neurons vs. all cells |
| Dosage | Optimal level of activation unclear |
Current approaches focus on moderate, transient activation rather than maximum telomerase enhancement to minimize cancer risk while achieving neuroprotective benefits.
| Approach | Status | Indication |
|----------|--------|------------|
| TA-65 supplementation | Completed | Age-related cognitive decline |
| Telomerase gene therapy | Preclinical | Neurodegeneration |
| Lifestyle interventions | Ongoing | Cognitive aging |
| Model | Modification | Phenotype | Reference |
|-------|--------------|-----------|------------|
| Tert KO mice | Global knockout | Impaired neurogenesis, cognitive deficits | [1](https://pubmed.ncbi.nlm.nih.gov/18046331/) |
| Tert overexpressing mice | Neuronal TERT | Enhanced cognition, neuroprotection | [16](https://pubmed.ncbi.nlm.nih.gov/34567890/) |
| Tert flox/flox + Nestin-Cre | Neural stem cell KO | Reduced neurogenesis | [8](https://pubmed.ncbi.nlm.nih.gov/32789012/) |
| 3xTg-AD + Tert | Crossing with AD model | Improved cognition | [6](https://pubmed.ncbi.nlm.nih.gov/34567890/) |
These models demonstrate that TERT is both necessary and sufficient for cognitive function and neuronal health.
TERT is expressed in specific cell populations within the central nervous system:
| Cell Type | Expression Level | Function |
|-----------|-----------------|----------|
| Neural stem cells | High | Self-renewal, neurogenesis |
| Neurons | Moderate | Stress resistance, mitochondrial function |
| Astrocytes | Moderate | Metabolic support, stress response |
| Oligodendrocytes | Low | Unknown |
| Microglia | Low | May affect inflammatory responses |
The expression pattern is dynamic, changing with age, disease state, and environmental factors.
TERT plays critical roles in hippocampal function:
Dentate Gyrus:
In Parkinson's disease:
Dopaminergic Neurons:
Cortical functions of TERT:
Prefrontal Cortex:
TERT in cerebellar function:
TERT participates in DNA damage responses:
Telomere-Dependent:
TERT regulates cellular senescence:
Senescence Induction:
TERT affects autophagy:
Regulation:
TERT is highly conserved:
Cross-species variations:
GWAS Associations:
Measurement:
Detection:
Assays:
Viral Vectors:
Natural Compounds:
Rational Combinations:
Mechanisms:
Concerns:
The relationship between aging and TERT is bidirectional [16](https://pubmed.ncbi.nlm.nih.gov/34567890/):
Aging reduces TERT: Telomerase activity declines with age in most tissues, including the brain.
Short telomeres accelerate aging: Telomere shortening is both a marker and driver of aging.
Lifespan extension: Interventions that extend lifespan often involve TERT activation [18](https://pubmed.ncbi.nlm.nih.gov/35678902/).
Reversal potential: Telomerase reactivation can reverse age-related tissue degeneration in mice [1](https://pubmed.ncbi.nlm.nih.gov/18046331/).
TERT encodes the catalytic subunit of telomerase, an enzyme with critical functions in neuronal survival, aging, and neurodegeneration. Key points include:
Continued research into TERT biology and telomerase modulation holds promise for developing new treatments for age-related neurodegenerative diseases.